SCHEMBL20286040

SCHEMBL20286040

N#CC(C#N)=Cc1ccccc1OC=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.55
▸ ALDH1A1 P00352 4/20 0.55
▸ MAPT P10636 3/20 0.55
▸ TRPA1 O75762 1/20 0.51
▸ KMT2A Q03164 7/20 0.48
▸ LMNA P02545 3/20 0.48
▸ HTT P42858 1/20 0.48
▸ PKM P14618 1/20 0.45
▸ EGFR P00533 2/20 0.42
▸ APP P05067 3/20 0.41
▸ MEN1 O00255 5/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ POLB P06746 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ THRB P10828 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1532464 0.79 KDM4E (0.64) KDM4EALDH1A1MAPTTRPA1KMT2A
SCHEMBL21457136 0.75 MAPT (0.70) KDM4EALDH1A1MAPTTRPA1KMT2A
SCHEMBL7598649 0.73 ALDH1A1 (0.61) KDM4EALDH1A1MAPTKMT2ALMNA
SCHEMBL5139573 0.70 ALDH1A1 (0.42) ALDH1A1KMT2ALMNAHTTMEN1
SCHEMBL8458208 0.70 TRPA1 (0.62) KDM4EALDH1A1MAPTTRPA1KMT2A
SCHEMBL10041814 0.70 LMNA (0.44) ALDH1A1MAPTKMT2ALMNAHTT
SCHEMBL9881101 0.70 ALDH1A1 (0.42) KDM4EALDH1A1MAPTKMT2ALMNA
SCHEMBL12866087 0.69 EGFR (0.68) KDM4EALDH1A1MAPTKMT2ALMNA
SCHEMBL3368866 0.68 TRPA1 (0.60) KDM4EALDH1A1MAPTTRPA1KMT2A
SCHEMBL3369090 0.68 TRPA1 (0.60) KDM4EALDH1A1MAPTTRPA1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834663-B2 Fibrotic treatment MONASH UNIVERSITY (AU) 2023-12-05 — — US disclosed
US-20180223287-A1 FIBROTIC TREATMENT MONASH UNIVERSITY (AU) 2018-08-09 — — US disclosed
US-20180170891-A1 4H-Pyran Compounds as Insulin-Regulated Aminopeptidase (IRAP) Inhibitors MONASH UNIVERSITY (AU) 2018-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180223287-A1 FIBROTIC TREATMENT ENPEP, IL4I1, LNPEP KDM4E 1261/4885ALDH1A1 1064/4885MAPT 4232/4885
US-20180170891-A1 4H-Pyran Compounds as Insulin-Regulated Aminopeptidase (IRAP) Inhibitors IAPP, ENPEP, DNPEP KDM4E 1470/4885ALDH1A1 2853/4885MAPT 113/4885
US-11834663-B2 Fibrotic treatment MMP1, ENPEP, RNPEP KDM4E 1936/4885ALDH1A1 1883/4885MAPT 3950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback